Literature DB >> 16321985

Mice deficient in the Rab5 guanine nucleotide exchange factor ALS2/alsin exhibit age-dependent neurological deficits and altered endosome trafficking.

Shinji Hadano1, Susanna C Benn, Shigeru Kakuta, Asako Otomo, Katsuko Sudo, Ryota Kunita, Kyoko Suzuki-Utsunomiya, Hikaru Mizumura, Jeremy M Shefner, Gregory A Cox, Yoichiro Iwakura, Robert H Brown, Joh-E Ikeda.   

Abstract

ALS2/alsin is a member of guanine nucleotide exchange factors for the small GTPase Rab5 (Rab5GEFs), which act as modulators in endocytic pathway. Loss-of-function mutations in human ALS2 account for a number of juvenile recessive motor neuron diseases (MNDs). However, the normal physiological role of ALS2 in vivo and the molecular mechanisms underlying motor dysfunction are still unknown. To address these issues, we have generated mice homozygous for disruption of the Als2 gene. The Als2-null mice observed through 21 months of age demonstrated no obvious developmental, reproductive or motor abnormalities. However, immunohistochemical and electrophysiological analyses identified an age-dependent, slowly progressive loss of cerebellar Purkinje cells and disturbance of spinal motor neurons associated with astrocytosis and microglial cell activation, indicating a subclinical dysfunction of motor system in Als2-null mice. Further, quantitative epidermal growth factor (EGF)-uptake analysis identified significantly smaller-sized EGF-positive endosomes in Als2-null fibroblasts, suggesting an alteration of endosome/vesicle trafficking in the cells. Collectively, while loss of ALS2 does not produce a severe disease phenotype in mice, these Als2-null animals should provide a useful model with which to understand the interplay between endosomal dynamics and the long-term viability of large neurons such as Purkinje cells and spinal motor neurons.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16321985     DOI: 10.1093/hmg/ddi440

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  45 in total

1.  Deficiency in the ALS2 gene does not affect the motor neuron degeneration in SOD1(G93A) transgenic mice.

Authors:  Xian Lin; Hoon Shim; Huaibin Cai
Journal:  Neurobiol Aging       Date:  2006-09-12       Impact factor: 4.673

Review 2.  Rho-linked genes and neurological disorders.

Authors:  Nael Nadif Kasri; Linda Van Aelst
Journal:  Pflugers Arch       Date:  2007-11-15       Impact factor: 3.657

Review 3.  Action in the axon: generation and transport of signaling endosomes.

Authors:  Katharina E Cosker; Stephanie L Courchesne; Rosalind A Segal
Journal:  Curr Opin Neurobiol       Date:  2008-06       Impact factor: 6.627

Review 4.  Hereditary Spastic Paraplegia: Clinical and Genetic Hallmarks.

Authors:  Paulo Victor Sgobbi de Souza; Wladimir Bocca Vieira de Rezende Pinto; Gabriel Novaes de Rezende Batistella; Thiago Bortholin; Acary Souza Bulle Oliveira
Journal:  Cerebellum       Date:  2017-04       Impact factor: 3.847

5.  Motor unit number estimate as a predictor of motor dysfunction in an animal model of type 1 diabetes.

Authors:  Nizar Souayah; Joseph G Potian; Carmen C Garcia; Natalia Krivitskaya; Christine Boone; Vanessa H Routh; Joseph J McArdle
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-07-14       Impact factor: 4.310

Review 6.  Alsin and the molecular pathways of amyotrophic lateral sclerosis.

Authors:  Jayanth Chandran; Jinhui Ding; Huaibin Cai
Journal:  Mol Neurobiol       Date:  2007-07-10       Impact factor: 5.590

7.  Regulation of endosomal motility and degradation by amyotrophic lateral sclerosis 2/alsin.

Authors:  Chen Lai; Chengsong Xie; Hoon Shim; Jayanth Chandran; Brian W Howell; Huaibin Cai
Journal:  Mol Brain       Date:  2009-07-24       Impact factor: 4.041

8.  Loss of ALS2/Alsin exacerbates motor dysfunction in a SOD1-expressing mouse ALS model by disturbing endolysosomal trafficking.

Authors:  Shinji Hadano; Asako Otomo; Ryota Kunita; Kyoko Suzuki-Utsunomiya; Akira Akatsuka; Masato Koike; Masashi Aoki; Yasuo Uchiyama; Yasuto Itoyama; Joh-E Ikeda
Journal:  PLoS One       Date:  2010-03-22       Impact factor: 3.240

9.  Experimental models for the study of neurodegeneration in amyotrophic lateral sclerosis.

Authors:  Luis B Tovar-Y-Romo; Luz Diana Santa-Cruz; Ricardo Tapia
Journal:  Mol Neurodegener       Date:  2009-07-20       Impact factor: 14.195

10.  Mutations in CHMP2B in lower motor neuron predominant amyotrophic lateral sclerosis (ALS).

Authors:  Laura E Cox; Laura Ferraiuolo; Emily F Goodall; Paul R Heath; Adrian Higginbottom; Heather Mortiboys; Hannah C Hollinger; Judith A Hartley; Alice Brockington; Christine E Burness; Karen E Morrison; Stephen B Wharton; Andrew J Grierson; Paul G Ince; Janine Kirby; Pamela J Shaw
Journal:  PLoS One       Date:  2010-03-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.